Nutex Health, Inc.
Nutex Health, Inc. Fundamental Analysis
Nutex Health, Inc. (NUTX) shows strong financial fundamentals with a PE ratio of 9.24, profit margin of 7.34%, and ROE of 23.80%. The company generates $0.8B in annual revenue with strong year-over-year growth of 93.80%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 79.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze NUTX's fundamental strength across five key dimensions:
Efficiency Score
WeakNUTX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentNUTX trades at attractive valuation levels.
Growth Score
ModerateNUTX shows steady but slowing expansion.
Financial Health Score
ModerateNUTX shows balanced financial health with some risks.
Profitability Score
ModerateNUTX maintains healthy but balanced margins.
Key Financial Metrics
Is NUTX Expensive or Cheap?
P/E Ratio
NUTX trades at 9.24 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NUTX's PEG of -0.18 indicates potential undervaluation.
Price to Book
The market values Nutex Health, Inc. at 1.80 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 1.29 times EBITDA. This is generally considered low.
How Well Does NUTX Make Money?
Net Profit Margin
For every $100 in sales, Nutex Health, Inc. keeps $7.34 as profit after all expenses.
Operating Margin
Core operations generate 30.53 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $23.80 in profit for every $100 of shareholder equity.
ROA
Nutex Health, Inc. generates $6.99 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Nutex Health, Inc. generates strong operating cash flow of $220.47M, reflecting robust business health.
Free Cash Flow
Nutex Health, Inc. generates strong free cash flow of $218.22M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $36.65 in free cash annually.
FCF Yield
NUTX converts 46.75% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
9.24
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.80
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.60
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.41
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.24
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.35
vs 25 benchmark
How NUTX Stacks Against Its Sector Peers
| Metric | NUTX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 9.24 | 28.25 | Better (Cheaper) |
| ROE | 23.80% | 780.00% | Weak |
| Net Margin | 7.34% | -20122.00% (disorted) | Weak |
| Debt/Equity | 1.07 | 0.30 | Weak (High Leverage) |
| Current Ratio | 3.41 | 4.66 | Strong Liquidity |
| ROA | 6.99% | -14687.00% (disorted) | Weak |
NUTX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Nutex Health, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
301.38%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
156.94%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
55.00%
Industry Style: Defensive, Growth, Innovation
High Growth